172 related articles for article (PubMed ID: 11710971)
1. Synthesis and preliminary cytotoxicity study of a cephalosporin-CC-1065 analogue prodrug.
Wang Y; Yuan H; Wright SC; Wang H; Larrick JW
BMC Chem Biol; 2001; 1(1):4. PubMed ID: 11710971
[TBL] [Abstract][Full Text] [Related]
2. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
3. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and cytotoxicity of a biotinylated CC-1065 analogue.
Wang Y; Yuan H; Wright SC; Wang H; Larrick JW
BMC Chem Biol; 2002; 2(1):1. PubMed ID: 11846891
[TBL] [Abstract][Full Text] [Related]
6. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
7. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT).
Varner JD
Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273
[TBL] [Abstract][Full Text] [Related]
8. Extending the beta-Lactamase-Dependent Prodrug Armory: S-Aminosulfeniminocephalosporins as Dual-Release Prodrugs.
Smyth TP; O'Connor MJ; O'Donnell ME
J Org Chem; 1999 Apr; 64(9):3132-3138. PubMed ID: 11674412
[TBL] [Abstract][Full Text] [Related]
9. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme.
Mauger AB; Burke PJ; Somani HH; Friedlos F; Knox RJ
J Med Chem; 1994 Oct; 37(21):3452-8. PubMed ID: 7932574
[TBL] [Abstract][Full Text] [Related]
10. Antibody-directed enzyme prodrug therapy (ADEPT): a review.
Springer CJ; Niculescu-Duvaz I
Adv Drug Deliv Rev; 1997 Jul; 26(2-3):151-172. PubMed ID: 10837540
[TBL] [Abstract][Full Text] [Related]
11. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
Tietze LF; Krewer B
Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
[TBL] [Abstract][Full Text] [Related]
12. Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy.
El-Sayed ASA; Mohamed NZ; Yassin MA; Amer MM; El-Sharkawy R; El-Sayed N; Ali MG
Heliyon; 2022 Sep; 8(9):e10660. PubMed ID: 36164544
[TBL] [Abstract][Full Text] [Related]
13. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
15. Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.
Sharma SK; Bagshawe KD
Expert Opin Biol Ther; 2017 Jan; 17(1):1-13. PubMed ID: 27737561
[TBL] [Abstract][Full Text] [Related]
16. Antibody-enzyme conjugates for cancer therapy.
Melton RG; Sherwood RF
J Natl Cancer Inst; 1996 Feb; 88(3-4):153-65. PubMed ID: 8632489
[TBL] [Abstract][Full Text] [Related]
17. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.
Wentworth P; Datta A; Blakey D; Boyle T; Partridge LJ; Blackburn GM
Proc Natl Acad Sci U S A; 1996 Jan; 93(2):799-803. PubMed ID: 8570638
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of novel SN-38 prodrug activated by α-rhamnosidase of exogenous enzyme.
Nii T; Hijii S; Kaneko R; Tanito K; Yamanaka K; Kishimura A; Mori T; Katayama Y
Anal Sci; 2024 May; ():. PubMed ID: 38748393
[TBL] [Abstract][Full Text] [Related]
19. Analysis of antibody-enzyme conjugate clearance by investigation of prodrug and active drug in an ADEPT clinical study.
Springer CJ; Poon GK; Sharma SK; Bagshawe KD
Cell Biophys; 1994; 24-25():193-207. PubMed ID: 7736524
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
Tietze LF; Schmuck K
Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
